Email this article Primary tumor (tumoral) calcification is a rare disease in the practice of a rheumatologist and orthopedist: experience with the use of an interleukin-1 inhibitor in combination with surgical correction
- Authors: Petukhova V.V.1, Idrisova R.V.2, Snegireva L.S.1, Krasnogorskaya O.L.1, Suspitsyn E.N.1,3, Veselov A.G.1, Kostik M.M.1
-
Affiliations:
- Saint Petersburg State Pediatric Medical University
- City’s Children’s Hospital No. 1
- Center of Oncology named after N.N. Petrova
- Issue: Vol 7, No 3 (2019)
- Pages: 85-92
- Section: Clinical cases
- URL: https://journal-vniispk.ru/turner/article/view/12523
- DOI: https://doi.org/10.17816/PTORS7385-92
- ID: 12523
Cite item
Abstract
Background. Primary tumoral calcinosis is an orphan disease. There are few data in the literature on the incidence of this disease, as well as clinical recommendations for treatment.
Clinical case. This report presents the case of an 11.5-year-old boy with primary tumoral calcinosis and equinus deformity of the foot. The patient had multiple foci of the subcutaneal calcification, cannot walk, experienced fatigue, and had high fever and equinus deformity of the left foot. Immunological and genetic studies were performed, but any specific mutations were not found. After the diagnosis was verified and interleukin-1β inhibitor therapy was prescribed, there was a significant positive trend observed in the patient: a significant improvement in the patient’s general condition, a decrease in the number of calcinates, and a reduction in inflammation. Calcification of the Achilles tendon and gastrocnemius muscle was the cause of the deformity of the left foot.
Discussion. Significant improvement was achieved during treatment: the boy started walking, fatigue was decreased, no new calcificates were formed, and inflammation was under the control. Using an inhibitor of interleukin-1β as a permanent therapy of primary tumoral calcification allowed performsurgical treatment without complications from an operation site, as well as a relapse of deformity.
Conclusion. The clinical case presented here demonstrated the application of an interdisciplinary approach to the treatment of an extremely rare disease.
Full Text
##article.viewOnOriginalSite##About the authors
Veronika V. Petukhova
Saint Petersburg State Pediatric Medical University
Email: nika_add@mail.ru
ORCID iD: 0000-0002-2358-5529
SPIN-code: 9451-3030
MD, Clinical Resident of the Department of Children’s Surgical Diseases
Russian Federation, Saint PetersburgRena V. Idrisova
City’s Children’s Hospital No. 1
Email: rena.idrisova2015@mail.ru
ORCID iD: 0000-0002-3440-7963
SPIN-code: 7257-0795
MD, Pediatrician
Russian Federation, Saint PetersburgLudmila S. Snegireva
Saint Petersburg State Pediatric Medical University
Email: l.s.snegireva@mail.ru
ORCID iD: 0000-0001-6778-4127
SPIN-code: 7257-0795
MD, Pediatric Rheumatologist of the Pediatric Department No. 3
Russian Federation, Saint PetersburgOlga L. Krasnogorskaya
Saint Petersburg State Pediatric Medical University
Email: krasnogorskaya@yandex.ru
ORCID iD: 0000-0001-6256-0669
SPIN-code: 2460-4480
MD, PhD, Associate Professor of the Department of pathological anatomy with a course of forensic medicine, Head of the Pathology Department of the Clinic
Russian Federation, Saint PetersburgEvgeny N. Suspitsyn
Saint Petersburg State Pediatric Medical University; Center of Oncology named after N.N. Petrova
Email: evgeny.suspitsin@gmail.com
ORCID iD: 0000-0001-9764-2090
SPIN-code: 2362-6304
MD, PhD, Assistant Professor, Department Medical Genetics; Senior Researcher
Russian Federation, Saint PetersburgAlexander G. Veselov
Saint Petersburg State Pediatric Medical University
Email: drveselov@bk.ru
ORCID iD: 0000-0001-6977-3966
SPIN-code: 7502-2280
MD, PhD, Assistant of the Department of Children’s Surgical Diseases of G.A. Bairov
Russian Federation, Saint PetersburgMikhail M. Kostik
Saint Petersburg State Pediatric Medical University
Author for correspondence.
Email: kost-mikhail@yandex.ru
ORCID iD: 0000-0002-1180-8086
SPIN-code: 7257-0795
MD, PhD, D.Sc., Professor of the Hospital Pediatric Department
Russian Federation, Saint PetersburgReferences
- McClatchie S, Bremner AD. Tumoral calcinosis — an unrecognized disease. Br Med J. 1969;1(5637):153-155. https://doi.org/10.1136/bmj.1.5637.142-a.
- Ramnitz MS, Gourh P, Goldbach-Mansky R, et al. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. J Bone Miner Res. 2016;31(10):1845-1854. https://doi.org/10.1002/jbmr.2870.
- Giard A. Sur la calcification hibernale. CR Soc Biol. 1898;10:1013-1015.
- Inclan A. Tumoral calcinosis. JAMA. 1943;121(7):490. https://doi.org/10.1001/jama.1943.02840070018005.
- McPhaul JJ, Engel FL. Heterotopic calcification, hyperphosphatemia and angioid streaks of the retina. Am J Med. 1961;31(3):488-492. https://doi.org/10.1016/0002-9343(61)90131-0.
- Chefetz I, Sprecher E. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. Biochim Biophys Acta. 2009;1792(9):847-852. https://doi.org/10.1016/j.bbadis.2008.10.008.
- Narchi H. Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics. 1997;99(5):745-745. https://doi.org/10.1542/peds.99.5.745.
- Rafaelsen S, Johansson S, Raeder H, Bjerknes R. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature. BMC Genet. 2014;15:98. https://doi.org/10.1186/s12863-014-0098-3.
- Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005;14(3):385-390. https://doi.org/10.1093/hmg/ddi034.
- Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36(6):579-581. https://doi.org/10.1038/ng1358.
- Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact. 2007;7(4):318-319. https://doi.org/10.1172/JCI31330.
- Pan CW, Chen RF. Tumoral calcinosis in the neck region involving an unusual site in a hemodialysis patient. Laryngoscope. 2016;126(5):E196-198. https://doi.org/10.1002/lary.25794.
- Shen Q, Liu Y, Yu Q, et al. Disappearance of tumoral calcification after parathyroidectomy. Nephrology (Carlton). 2016;21(9):791-792. https://doi.org/10.1111/nep.12674.
- Buchkremer F, Farese S. Uremic tumoral calcinosis improved by kidney transplantation. Kidney Int. 2008;74(11):1498. https://doi.org/10.1038/ki.2008.142.
- Orandi AB, Dharnidharka VR, Al-Hammadi N, et al. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J. 2018;16(1):84. https://doi.org/10.1186/s12969-018-0299-9.
- Zhao L, Huang L, Zhang X. Systemic lupus erythematosus-related hypercalcemia with ectopic calcinosis. Rheumatol Int. 2016;36(7):1023-1026. https://doi.org/10.1007/s00296-016-3486-3.
- Htet TD, Eisman JA, Elder GJ, Center JR. Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide. Osteoporos Int. 2018;29(2): 517-518. https://doi.org/10.1007/s00198-017-4330-7.
Supplementary files
